Patents by Inventor Ernest S. Hamanaka

Ernest S. Hamanaka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinoline compounds
    Patent number: 7468378
    Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1—R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
    Type: Grant
    Filed: February 3, 2005
    Date of Patent: December 23, 2008
    Assignee: Pfizer Inc.
    Inventors: Peter Bertinato, Michel A. Couturier, Ernest S. Hamanaka, Marcus D. Ewing, Ralph P. Robinson, Derek L. Tickner
  • Triamide-substituted heterobicyclic compounds
    Patent number: 7393958
    Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: July 1, 2008
    Assignee: Pfizer, Inc.
    Inventors: Peter Bertinato, Michel A. Couturier, Ernest S. Hamanaka, Marcus D. Ewing, Ralph P. Robinson, Derek L. Tickner
  • Triamide-substituted heterobicyclic compounds
    Patent number: 7368573
    Abstract: This invention relates to MTP/Apo-B secretion inhibitors of Formula (I) wherein R1-R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: May 6, 2008
    Assignee: Pfizer Inc.
    Inventors: Peter Bertinato, Michel A. Couturier, Ernest S. Hamanaka, Marcus D. Ewing, Ralph P. Robinson, Derek L. Tickner
  • Substituted heteroaryl- and phenylsulfamoyl compounds
    Patent number: 7262318
    Abstract: The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: August 28, 2007
    Assignee: Pfizer, Inc.
    Inventors: Ernest S. Hamanaka, Marcus E. Kehrli, Jr.
  • N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia
    Patent number: 6974813
    Abstract: NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: December 13, 2005
    Assignee: Warner-Lambert Company
    Inventors: Ernest S. Hamanaka, Angel Guzman-Perez, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
  • Use of corticotropin releasing factor antagonists and related compositions
    Patent number: 6777404
    Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: August 17, 2004
    Assignee: Pfizer Inc
    Inventors: Ernest S. Hamanaka, Yuhpyng Liang Chen
  • Use of corticotropin releasing factor antagonists and related compositions
    Publication number: 20030199527
    Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
    Type: Application
    Filed: April 15, 2003
    Publication date: October 23, 2003
    Inventors: Ernest S. Hamanaka, Yuhpyng Liang Chen
  • N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
    Publication number: 20030149043
    Abstract: NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
    Type: Application
    Filed: December 9, 2002
    Publication date: August 7, 2003
    Applicant: Pfizer Inc.
    Inventors: Ernest S. Hamanaka, Angel Guzman-Perez, Christian J. Mularski, Roger B. Ruggeri, Ronald T. Wester
  • Use of corticotropin releasing factor antagonists and related compositions
    Patent number: 6589947
    Abstract: The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist alone or together with a glucocorticoid receptor antagonist.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: July 8, 2003
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Ernest S. Hamanaka, Yuhpyng Liang Chen
  • 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
    Patent number: 6537987
    Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, anti-Alzheimer's agents or anti-acne agents.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: March 25, 2003
    Assignee: Pfizer Inc.
    Inventors: Ernest S. Hamanaka, Cheryl M. Hayward
  • N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
    Patent number: 6492401
    Abstract: NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: December 10, 2002
    Assignee: Pfizer, Inc.
    Inventors: Ernest S. Hamanaka, Angel Guzman-Perez, Roger B. Ruggeri, Ronald T. Webster, Christian J. Mularski
  • Mutual prodrugs of amlodipine and atorvastatin
    Patent number: 6486182
    Abstract: This invention relates to mutual prodrugs of amlodipine and atorvastatin and to pharmaceutical compositions thereof. This invention also relates to methods of treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal using those prodrugs and compositions. This invention also relates to methods of managing cardiac risk in a mammal, including humans, presenting with symptoms of cardiac risk by administering those prodrugs and compositions.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 26, 2002
    Assignee: Pfizer Inc
    Inventors: George Chang, Ernest S. Hamanaka, John L. LaMattina
  • Mutual salt of amlodipine and atorvastatin
    Patent number: 6262092
    Abstract: This invention relates to a mutual salt of amlodipine and atorvastatin, pharmaceutical compositions thereof and methods of treating angina pectoris, atherosclerosis and combined hypertension and hyperlipidemia in mammals with such a mutual salt and compositions. This invention also relates to methods of managing cardiac risk in a mammal presenting with symptoms of cardiac risk, including humans by administering such a mutual salt and compositions.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: July 17, 2001
    Assignee: Pfizer Inc.
    Inventors: George Chang, Ernest S. Hamanaka
  • N-aryl and N-heteroarylurea derivatives as inhibitors of acyl coenzyme A: Cholesterol acyl transferase (ACAT)
    Patent number: 6001860
    Abstract: A compound of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.17, R.sup.18 and R.sup.1 are as defined below. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
    Type: Grant
    Filed: January 17, 1995
    Date of Patent: December 14, 1999
    Assignee: Pfizer Inc.
    Inventor: Ernest S. Hamanaka
  • Squalene synthetase inhibitors
    Patent number: 5965553
    Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents, hypotriglyceridemic agents, antiatherosclerosis agents, antifungal agents, Alzheimer's agents or anti-acne agents.
    Type: Grant
    Filed: June 12, 1997
    Date of Patent: October 12, 1999
    Assignee: Pfizer Inc.
    Inventors: Andrew S. Bell, Ernest S. Hamanaka, Cheryl M. Hayward, Douglas A. Scully, Blanda Stammen
  • Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors
    Patent number: 5770594
    Abstract: This invention relates to certain benzoxazepinones and benzothiazepinones useful as hypocholesterolemic agents and antiatheroscierosis agents.
    Type: Grant
    Filed: June 17, 1997
    Date of Patent: June 23, 1998
    Assignee: Pfizer Inc.
    Inventors: Ernest S. Hamanaka, Cheryl M. Hayward, Joel M. Hawkins
  • N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
    Patent number: 5656634
    Abstract: Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: August 12, 1997
    Assignee: Pfizer Inc.
    Inventors: George Chang, Ernest S. Hamanaka, Peter A. McCarthy, Thien V. Truong, Frederick J. Walker
  • 4-aryl-3-(heteroarylureido)quinoline derivatves
    Patent number: 5596001
    Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, m, X and Q are as defined below, and novel intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and natiatherosclerosis agents.
    Type: Grant
    Filed: October 25, 1993
    Date of Patent: January 21, 1997
    Assignee: Pfizer Inc.
    Inventor: Ernest S. Hamanaka
  • 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
    Patent number: 5565472
    Abstract: Compounds of the formula ##STR1## the pharmaceutically acceptable salts thereof wherein R.sup.2, R.sup.3, R.sup.4, m, X and Q are as defined below, and novel intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: October 15, 1996
    Assignee: Pfizer Inc.
    Inventor: Ernest S. Hamanaka
  • Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
    Patent number: 5362878
    Abstract: Compounds of the formula ##STR1## wherein R.sup.21 and R.sup.22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula ##STR2## and the pharmaceutically acceptable salts thereof, wherein Q and R.sup.1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: November 8, 1994
    Assignee: Pfizer Inc.
    Inventors: George Chang, Ernest S. Hamanaka, Peter A. McCarthy, Thien Truong, Frederick J. Walker